Sath Shukla
CEO and President at Spero Therapeutics Inc.
Sits on 1 board. Last updated September 28, 2026
Time on boards
- Boards served
- 1
- Current seats
- 1
- Board service
- 3 years
- Director since
- 2023
3 years of board service in total across 1 board, counting each seat separately. Longest: Spero Therapeutics Inc., 3 years.
Spero Therapeutics Inc.
Director · CEO and President
Chief executive roles
Spero Therapeutics Inc.
· CEO and President
Dates unknown
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Feb 5, 2025 | Spero Therapeutics Inc. | Open-market sale | −6,139 | $0.78 | $4,788 |
| Feb 5, 2025 | Spero Therapeutics Inc. | Open-market sale | −42,786 | $0.78 | $33,373 |
| Feb 5, 2025 | Spero Therapeutics Inc. | Open-market sale | −106,408 | $0.78 | $82,998 |
| Feb 3, 2025 | Spero Therapeutics Inc. | Grant or award | +751,407 | — | — |
| Aug 27, 2024 | Spero Therapeutics Inc. | Open-market sale | −2,757 | $1.35 | $3,722 |
| Aug 5, 2024 | Spero Therapeutics Inc. | Open-market sale | −17,641 | $1.31 | $23,110 |
| Aug 2, 2024 | Spero Therapeutics Inc. | Open-market sale | −14,800 | $1.32 | $19,536 |
| Feb 5, 2024 | Spero Therapeutics Inc. | Open-market sale | −45,093 | $1.45 | $65,385 |
| Feb 2, 2024 | Spero Therapeutics Inc. | Open-market sale | −30,901 | $1.37 | $42,334 |
| Feb 1, 2024 | Spero Therapeutics Inc. | Grant or award | +679,501 | — | — |
| Aug 29, 2023 | Spero Therapeutics Inc. | Open-market sale | −4,163 | $1.30 | $5,412 |
| Aug 28, 2023 | Spero Therapeutics Inc. | Open-market sale | −1,854 | $1.26 | $2,336 |
| Aug 1, 2023 | Spero Therapeutics Inc. | Grant or award | +266,000 | — | — |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.